Table 2 Frequency and patients’ disposition of SARS-CoV-2 infection

Age, mean (SD), years

62.8 (13.1)*^§

52.8 (13.1)*^§

53.8 (14.6)*^§

58.5 (14.9)*^§

Female gender, n (%)

15 (65.2)

21 (72.4)

178 (68.2)

1140 (65.6)

Current smokers, n (%)

4 (21.1)

3 (11.5)

38 (18.3)

231 (16.2)

BMI, median (IQR)

26.3 (7)

24.6 (4.3)

24.9 (5.4)

25.3 (5.1)

 Overweight, n (%)

4 (28.6)

7 (25.9)

53 (26.1)^#

461 (33.6)^#

 Obese, n (%)

3 (21.4)

4 (14.8)

33 (16.3)

193 (14.1)

Hypertension, n (%)

10 (50)

10 (37)

76 (30.6)

547 (32.5)

Diabetes, n (%)

2 (10)

1 (3.7)

22 (8.9)

133 (7.9)

 SpA, n (%)

4 (17.4)

5 (17.2)

48 (18.4)

240 (13.8)

 PsA, n (%)

2 (8.7)

4 (13.8)

52 (19.9)

340 (19.6)

 UA, n (%)

0 (0)

4 (13.8)

11 (4.2)

112 (6.4)

 RA, n (%)

17 (73.9)

16 (55.2)

150 (57.5)

1045 (60.2)

Disease duration, median (IQR), months

96 (60–153)

96 (50–147)

120 (60–180)

120 (60–192)

 ≤ 5 years, n (%)

7 (30.4)

10 (35.4)

70 (27.1)

496 (28.7)

 5–10 years, n (%)

8 (34.8)

12 (41.4)

66 (25.6)

449 (26)

 10–15 years, n (%)

6 (26.1)

0 (0)

63 (24.4)

361 (20.9)

 > 15 years, n (%)

2 (8.7)

7 (24.1)

59 (22.9)

422 (24.4)

Use of PDN, n (%)

13 (56.5)**

9 (31)

73 (28)**

549 (31.7)**

PDN dose, mean (SD), mg/day

4.6 (1.4)

3.9 (2.2)

4.3 (2.1)

4.3 (3.5)

 < 2.5 mg/day, n (%)

0 (0)

2 (22.2)

6 (8.2)

49 (9)

 ≥ 2.5 mg/day, n (%)

13 (100)

7 (77.8)

67 (91.8)

498 (91)

Use of HCQ, n (%)

5 (21.7)

5 (17.2)

47 (18)

325 (18.7)

Use of csDMARDs, n (%)

15 (65.2)

13 (44.8)

153 (54.8)

877 (50.5)

Use of b/tsDMARDs, n (%)

10 (43.5)**

11 (37.9)^{^}

183 (70.1)**^{^}

1074 (61.8)^{^}